What is this study studying for Pulmonary Arterial Hypertension?

This study is evaluating whether pharmacist guidance can improve how patients with Pulmonary Arterial Hypertension use their inhaled iloprost treatment. Researchers want to see if this support helps patients take their medication more regularly, reduces side effects, and leads to better health outcomes. The study is sponsored by the University of Sao Paulo General Hospital.

Who may be eligible for this Pulmonary Arterial Hypertension clinical trial?

Adults aged 18 years or older with a confirmed diagnosis of Pulmonary Arterial Hypertension who are using inhaled iloprost may be eligible. The trial includes all genders and requires participants to be able to perform a 6-minute walk test. Patients with recent gastrointestinal bleeding are excluded. Please review eligibility criteria for more details.

Is there any cost to participate in this Pulmonary Arterial Hypertension clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID07457762

AIRDROP: Can We Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?

Led by University of Sao Paulo General Hospital · Updated on 2026-03-09

Participants Needed

Research Sites

34 weeks

Total Duration

AI-Summary

What this Trial Is About

Pulmonary Arterial Hypertension (PAH) is a rare and progressive condition that affects blood flow in the lungs and can lead to heart failure. Despite advances in treatment, patients have a median survival of only 2.8 years. Current drugs focus on three pathways, including prostacyclin, which iloprost mimics in an inhaled form. However, iloprost requires frequent use and specific inhalation techniques, which can be challenging and cause side effects. This study evaluates if pharmacist guidance can improve how patients use iloprost, reduce side effects, and improve health outcomes. Participants will be randomly assigned to one of two groups: one group will receive professional guidance on inhaler use and adherence, while the other will receive no intervention. The study focuses on the effects of pharmacist support in managing inhaled iloprost treatment over time. The intervention group aims to improve how patients manage their inhaled medication and adherence to the treatment plan. Participants will be followed for 20 weeks during which medication adherence will be measured using a specific questionnaire. Researchers will monitor patients for treatment adherence, side effects, and any difficulties with inhalation. The main outcome is to assess how well patients stick to their inhaled iloprost treatment when they receive pharmacist guidance compared to those who do not. This study is sponsored by the University of Sao Paulo General Hospital and aims to optimize treatment for PAH patients.